As a complete newb I've held shares for over a year now with the expectation of a long term investment. My question is about listing on NASDAQ. What impact would that have on current AIMS shareholders? Can the company be listed on both? Does the price on one effect the other? I don't know what the impact would mean basically and what action would one need to do if any, should the listing happen, in order to best maximise on the investment?
Totally aggree with harlequin's post re nasdaq Serepta was just a cent company a few months ago, and now have a $170 mil. bank figure to expand with. Thats the US government backing progress. Surely, whatever the cost, Summit have to add up the figures and open themselves up to a ready and interested market, stateside, and leave this mealy mouthed, something for nothing country and its so called big buyer Pharmas.
Companies list there with just a few cents value. So where are the barriers ? Summit has an international market for its products and should there for have an international presence on financial markets. Whatever the costs they would be recouped overnight. The aim mkt is not a good platform for Summit.
My real point was I do not think Summit are being aggressive enough. If say they were to list on Nasdaz it would be so much easier to raise big money like Saretpa have done which would be so much easier in the US where the sp would be much higher. Just don't get why Mellon doesnot go for it .
i think it's a foregone conclusion Summit will eventually be listed on the Nasdaq, especially if we get a US partner for one of the programmes, and the phase 2 patient trials prove positive......Glyn Edwards was in the process of taking Antisoma on to the Nasdaq before it went tits up, and so i'm sure he has similar plans for Summit, where it true value will be realised and science appreciated, and long term holders will be greatly rewarded. GL
ps Sarepta raised a load of cash on the back of their phase 2 results...;-)
Riding the wave of what it says is high investor interest after recent good data from trials of its potential drug to treat Duchenne muscular dystrophy(DMD), Sarepta Therapeutics Inc. (Nasdaq: SRPT) on Thursday announced plans to offer $125 million in stock.
Re Sarepta. Thay are totally dependent on govt grants and have no trading income. To me it's increadable they have a billion $ valuation based purely on govt grants and potential. It just shows how different the US values these companies compared to UK. Imagine if Summit were on nasdaz!! Our sp is a total joke. With Mellon on board I am surprised they don't go for a listing there. Financially it would be worth it
Read through last few RNS's . They are very very good indeed. The fact that the sp does not reflect this is odd. The potential here is massive. If things fall into place Summit could become a household name in the bio world. Keep the faith. This company with a bit of luck could become very valuable
Datafeed and UK data supplied by NETbuilder and Interactive Data.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk!
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.